LexBio
- Biotech or pharma, therapeutic R&D
- Other R&D services
LexBio is an AI-driven biotech company advancing innovative therapies with KINET, a validated deep-learning platform for rapid drug discovery. KINET integrates predictive modeling, molecular generation, and multi-objective optimization to accelerate progression from target to preclinical candidate.
Our pipeline includes:
- two oncology assets within 12 months of IND, both addressing resistant RET and NTRK mutations;
- CNS program that targets multiple key markers including APP and Tau.
- inflammation/immunology asset focused on a central immune regulator.
Backed by strong experimental validation, LexBio combines platform innovation with internal R&D to deliver first- and best-in-class drug candidates.
We welcome opportunities to collaborate with partners who seek to integrate cutting-edge AI into drug discovery or explore co-development of high-impact therapeutic assets.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}